BioSpace News Archive

To drive awareness of interstitial lung disease (ILD), nine organizations are collaborating to present the first-ever ILD Day on Wednesday, Sept. 15 . There are more than 200 types of ILD, which is the umbrella term used for a large group of diseases characterized by inflammation and/or scarring in the lungs.

Sequana Medical NV announces that it has appointed Jackie Fielding, a former Vice President of Medtronic with more than 30 years of experience in the healthcare industry, as an independent Non-Executive Director of the Company, effective as of 1 September 2021 upon approval by the Board of Directors.

Burning Rock Biotech Limited today reported financial results for the three months ended June 30, 2021.

DBV Technologies, a clinical-stage biopharmaceutical company, announced that DBV Technologies’ senior management team will participate in upcoming virtual investor conferences in September.

Electroencephalogram (EEG) refers to neurophysiologic estimation of the electrical activity of the brain recorded and analyzed with the help of electrodes placed on the scalp or, in special cases, is inserted subdurally or in the cerebral cortex.

Consumer genetics testing and medical diagnostics pioneer DnaNudge announces that it has successfully completed a $60 million Series A investment round led by investment company Ventura Capital.

c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, has announced the submission of a Master File for its best-selling product DENARASE®.

HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, announced that its development partner in India, Gennova Biopharmaceuticals, successfully completed a Phase 1 trial of its COVID-19 RNA vaccine candidate HGCO19 and Indian regulatory authorities have approved the start of pivotal Phase 2/3 trials.

Orphazyme A/S, a late-stage biopharmaceutical company, announces its Interim Report First Half 2021 for the period January 1 – June 30, 2021.

Vifor Pharma is pleased to announce that the European Society of Cardiology included new recommendations and proposals in the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure for two of their key products, Ferinject® and Veltassa®.